<DOC>
	<DOCNO>NCT01432015</DOCNO>
	<brief_summary>Nausea vomit two concern adverse outcome associate chemotherapy treatment gynecologic malignancy . In fact , nearly 90 % cancer patient develop chemotherapy induce nausea vomit ( CINV ) follow treatment carboplatin paclitaxel . The successful control chemotherapy induce nausea vomiting ( CINV ) thus , paramount importance ensure optimal treatment sustain cancer patient 's quality life .</brief_summary>
	<brief_title>Fosaprepitant Versus Aprepitant Prevention Chemotherapy Induced Nausea Vomiting</brief_title>
	<detailed_description>Studies indicate oral intravenous anti-emetics equivalent regard efficacy ; evaluate cost convenience , intravenous route may preferable . Fosaprepitant , water-soluble phosphoryl prodrug aprepitant , convert aprepitant via phosphatase follow intravenous administration . Given rapid conversion fosaprepitant active form ( i.e. , aprepitant ) , two medication appear provide similarly effective antiemetic impact . Clinical report additionally suggest fosaprepitant could appropriate intravenous alternative oral aprepitant .</detailed_description>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<criteria>Female Gender Age &gt; 18 year A histologic diagnosis stage III/IV gynecologic cancer ( e.g. , epithelial ovarian , fallopian tube , peritoneal cancer uterine cancer ) . Subjects treat Taxol Carboplatin standard care newly diagnose gynecological cancer . Adequate bone marrow function demonstrate : Absolute neutrophil count ( ANC ) &gt; 1,500/μL ; platelet count &gt; 100,000/μL ; hemoglobin &gt; 9 g/dL • Adequate renal function demonstrate : Serum creatinine &lt; 1.5 x ULN 24hr measure urine creatinine clearance &gt; 60 mL/min patient serum creatinine &gt; 1.5 x ULN • Adequate hepatic function demonstrate : Total bilirubin &lt; 1.5 x ULN AST ALT ≤ 2.5 x ULN EGOG status &lt; 2 : Postoperatively , patient demonstrate ECOG score 1 2 . However , first cycle chemotherapy , patient ' performance status improve &lt; 1 . Projected life expectancy least 3 month Ability comply visit schedule assessment require protocol Negative pregnancy test woman childbearing potential Signed , IRB approve informed consent HIPPA consent Subjects diagnosis epithelial ovarian , fallopian tube peritoneal cancer low malignant potential ( borderline carcinoma ) eligible . Allergy intolerance 5HT3 NK1 antagonist dexamethasone An episode vomit retch within 24 hour start initial treatment chemotherapy Subjects concomitant malignancy previous malignancy within past three ( 3 ) year ( except nonmelanoma skin cancer ) Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study . Screening clinical laboratory value : ANC &lt; 1500/DL Platelet count &lt; 100,000/µL Total bilirubin *1.5 mg/dL x ULN SGOT ( AST ) SGPT ( ALT ) * 2.5 x ULN Serum creatinine * 1.5 mg/dL Hemoglobin * 9 gm/dL ( may transfuse receive colony stimulate factor maintain exceed level ) EGOG status &gt; 2 Gastrointestinal obstruction active peptic ulcer Patients pregnant breast feeding aprepitant may harmful develop fetus newborn Known active HIV viral hepatitis infection Inability comply study New York Heart Association ( NYHA ) Grade II great congestive heart failure ( see Appendix D )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>aprepitant</keyword>
	<keyword>fosaprepitant</keyword>
	<keyword>gynecologic cancer</keyword>
	<keyword>emesis</keyword>
</DOC>